STM publisher Elsevier has announced an enhanced risk monitoring and pharmacovigilance solution with Embase, its biomedical database, now seamlessly connecting to PharmaPendium, a source of extensive regulatory data. Embase claims to be the world's most comprehensive international biomedical database that enables tracking and retrieval of valuable drug- and disease-specific information; PharmaPendium aggregates the most extensive drug-related regulatory information that supports critical drug development decisions. Both are part of the Elsevier Life Science Solutions Portfolio.
A single drug search in Embase will provide an overview of key information pertaining to the drug of interest, including a snapshot of pre-clinical, clinical and post-marketing reported adverse events. Embase customers with a subscription to PharmaPendium can also link directly into a wealth of regulatory data including FDA and EMA approval documents from the results of their original search query. Pharmacovigilance workflows are improved with risk monitoring based upon more comprehensive data. Together, the two products support more efficient drug development research and more effective management of post-launch risks.
Embase customers were automatically upgraded to a new version on April 30, 2014. In addition to the seamless connection to PharmaPendium, the user experience was improved other additional new Embase enhancements include text-filter export, streamlined search forms and faster search.
Embase and PharmaPendium are part of Elsevier's Life Science Solutions, a portfolio of domain-specific, decision support tools which span the discovery and development workflow and work together to support key research outcomes. The portfolio includes Pathway Studio, ScienceDirect, Scopus, TargetInsights, Reaxys, Reaxys Medicinal Chemistry and QUOSA.
